UPDATED: Celgene bags CAR-T player Juno in $9B buyout as biotech M&A suddenly explodes – Endpoints News
Endpoints News |
UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodes
Endpoints News Leerink in particular was looking for Celgene to fork over $93 a share, which is what Celgene pegged the price at when it bought a minority share in the biotech. CAR-T has been one of the big success stories for biotech, offering a new approach to … Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing tractionBioWorld Online Celgene to buy Juno for $9 billion to boost cancer pipelineReuters Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Madison.com –Zacks Investment Research –Zacks Investment Research all 241 news articles » |
|
Why Spark and Watchdog ICER Don’t See Eye-to-Eye on $850K Gene Therapy
Xconomy The first gene therapy approved in the U.S. costs $850,000. Announcing the price on Jan. 3, its owner Spark Therapeutics held out the possibility of some relief, such as installment payments, or slim rebates if the drug, a one-time shot into each eye … |